business

UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

Investing.com · Jun 9, 2026, 6:12 AM · Also reported by 4 other sources

Read full story on Investing.com → More top stories

Also covered by

Bloomberg Markets GSK Agrees to Buy Nuvalent for $10.6 Billion Bloomberg Markets GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT Financial Times GSK in talks to buy cancer biotech Nuvalent for more than $9bn STAT News STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

Also covered by

More in business